Clinical Trial Update: Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) [Phase 2]

View source ↗

Summary

A Phase 2 trial RX-CROME evaluating regorafenib with XmAb20717 for high-risk colorectal cancer patients with radiographic occult molecular residual disease afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Stivarga (regorafenib)
• XmAb20717

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colorectal Cancer, Colon Cancer | Phase 2 | Status: WITHDRAWN